131 related articles for article (PubMed ID: 34617446)
1. Optimal Serum Thyrotropin Level for Patients with Papillary Thyroid Carcinoma After Lobectomy.
Xu S; Huang Y; Huang H; Zhang X; Qian J; Wang X; Xu Z; Liu S; Liu J
Thyroid; 2022 Feb; 32(2):138-144. PubMed ID: 34617446
[No Abstract] [Full Text] [Related]
2. Optimal thyrotropin level for low-risk papillary thyroid carcinoma after ultrasound-guided radiofrequency ablation.
Li X; Yan L; Xiao J; Li Y; Zhu Y; Yang Z; Zhang M; Luo Y
Int J Hyperthermia; 2023; 40(1):2160880. PubMed ID: 36599433
[TBL] [Abstract][Full Text] [Related]
3. Postoperative Thyroid-Stimulating Hormone Levels Did Not Affect Recurrence after Thyroid Lobectomy in Patients with Papillary Thyroid Cancer.
Lee MC; Kim MJ; Choi HS; Cho SW; Lee GH; Park YJ; Park DJ
Endocrinol Metab (Seoul); 2019 Jun; 34(2):150-157. PubMed ID: 31099202
[TBL] [Abstract][Full Text] [Related]
4. Thyroid stimulating hormone suppression and recurrence after thyroid lobectomy for papillary thyroid carcinoma.
Bae MR; Nam SH; Roh JL; Choi SH; Nam SY; Kim SY
Endocrine; 2022 Feb; 75(2):487-494. PubMed ID: 34689317
[TBL] [Abstract][Full Text] [Related]
5. Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases.
Matsuzu K; Sugino K; Masudo K; Nagahama M; Kitagawa W; Shibuya H; Ohkuwa K; Uruno T; Suzuki A; Magoshi S; Akaishi J; Masaki C; Kawano M; Suganuma N; Rino Y; Masuda M; Kameyama K; Takami H; Ito K
World J Surg; 2014 Jan; 38(1):68-79. PubMed ID: 24081532
[TBL] [Abstract][Full Text] [Related]
6. Frequency of Thyroid Hormone Replacement After Lobectomy for Differentiated Thyroid Cancer.
Schumm MA; Lechner MG; Shu ML; Ochoa JE; Kim J; Tseng CH; Leung AM; Yeh MW
Endocr Pract; 2021 Jul; 27(7):691-697. PubMed ID: 33642257
[TBL] [Abstract][Full Text] [Related]
7. The Recovery of Thyroid Function in Low-Risk Papillary Thyroid Cancer After Lobectomy: A 3-Year Follow-Up Study.
Dou Y; Chen Y; Hu D; Su X
Front Endocrinol (Lausanne); 2020; 11():619841. PubMed ID: 33633689
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of serum thyroid-stimulating hormone level post-lobectomy in low- and intermediate-risk papillary thyroid carcinoma.
Park JH; Lee YM; Lee YH; Hong SJ; Yoon JH
J Surg Oncol; 2018 Sep; 118(3):390-396. PubMed ID: 30114333
[TBL] [Abstract][Full Text] [Related]
9. Total thyroidectomy versus lobectomy for intermediate-risk papillary thyroid carcinoma: A single-institution matched-pair analysis.
Liu J; Zhang Z; Huang H; Xu S; Liu Y; Liu S; Wang X; Xu Z
Oral Oncol; 2019 Mar; 90():17-22. PubMed ID: 30846171
[TBL] [Abstract][Full Text] [Related]
10. Predictive Value of Serum Thyroglobulin for Structural Recurrence Following Lobectomy for Papillary Thyroid Carcinoma.
Xu S; Huang H; Zhang X; Huang Y; Guan B; Qian J; Wang X; Liu S; Xu Z; Liu J
Thyroid; 2021 Sep; 31(9):1391-1399. PubMed ID: 34340593
[No Abstract] [Full Text] [Related]
11. Levothyroxine Cessation After Thyroid Lobectomy for Papillary Thyroid Cancer Can Be Achieved at the Same Rate as that for Benign Tumors Regardless of the Duration of Thyroid-stimulating Hormone Suppression.
Na YM; Cho JS; Park MH
Anticancer Res; 2021 Nov; 41(11):5713-5721. PubMed ID: 34732444
[TBL] [Abstract][Full Text] [Related]
12. Inverse Relationship of BMI to TSH and Risk of Papillary Thyroid Cancer in Surgical Patients.
Handelsman RS; Alvarez AL; Picado O; Farrá JC; Lew JI
J Surg Res; 2019 Dec; 244():96-101. PubMed ID: 31280000
[TBL] [Abstract][Full Text] [Related]
13. High Serum TSH Level Is Associated With Progression of Papillary Thyroid Microcarcinoma During Active Surveillance.
Kim HI; Jang HW; Ahn HS; Ahn S; Park SY; Oh YL; Hahn SY; Shin JH; Kim JH; Kim JS; Chung JH; Kim TH; Kim SW
J Clin Endocrinol Metab; 2018 Feb; 103(2):446-451. PubMed ID: 29211863
[TBL] [Abstract][Full Text] [Related]
14. Degree of thyrotropin suppression in differentiated thyroid cancer without recurrence or metastases.
Kamel N; Güllü S; Dağci Ilgin S; Corapçioğlu D; Tonyukuk Cesur V; Uysal AR; Başkal N; Erdoğan G
Thyroid; 1999 Dec; 9(12):1245-8. PubMed ID: 10646665
[TBL] [Abstract][Full Text] [Related]
15. Does postoperative thyrotropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma? A randomized controlled trial.
Sugitani I; Fujimoto Y
J Clin Endocrinol Metab; 2010 Oct; 95(10):4576-83. PubMed ID: 20660039
[TBL] [Abstract][Full Text] [Related]
16. Is TSH suppression still necessary in intermediate- and high-risk papillary thyroid cancer patients with pre-ablation stimulated thyroglobulin <1 ng/mL before the first disease assessment?
Tian T; Huang R; Liu B
Endocrine; 2019 Jul; 65(1):149-154. PubMed ID: 30924085
[TBL] [Abstract][Full Text] [Related]
17. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
[TBL] [Abstract][Full Text] [Related]
18. Is thyroid hormone supplementation avoidable for patients with low-risk papillary thyroid cancer after thyroid lobectomy? A two-center observational study.
Xiao L; Wu J; Jiang L; Xu Y; Liu B
Clin Endocrinol (Oxf); 2022 Mar; 96(3):413-418. PubMed ID: 34398464
[TBL] [Abstract][Full Text] [Related]
19. L-thyroxine-treated patients with nodular goiter have lower serum TSH and lower frequency of papillary thyroid cancer: results of a cross-sectional study on 27 914 patients.
Fiore E; Rago T; Provenzale MA; Scutari M; Ugolini C; Basolo F; Di Coscio G; Miccoli P; Grasso L; Pinchera A; Vitti P
Endocr Relat Cancer; 2010 Mar; 17(1):231-9. PubMed ID: 20167722
[TBL] [Abstract][Full Text] [Related]
20. Effects of endocrine therapy on the prognosis of elderly patients after surgery for papillary thyroid carcinoma.
Xia Q; Dong S; Bian PD; Wang J; Li CJ
Eur Arch Otorhinolaryngol; 2016 Apr; 273(4):1037-43. PubMed ID: 25744048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
